Nanomedicine

Inert inorganic particles reach selected tumour cells

Upon X-ray radiation (hν(X)), NanoXray particles emit electrons (e-) that in...
Upon X-ray radiation (hν(X)), NanoXray particles emit electrons (e-) that in turn lead to the formation of radicals (R°) that damage DNA molecules and other cell components

Radiotherapy is a treatment of choice for six million (60%) of cancer patients annually. However, it has a crucial deficit: its therapeutic window is limited. The reason is simple. While radiotherapy is very efficient in killing cancer cells, it inevitably also damages surrounding healthy tissue. Therefore, in many cases doctors need to restrict the dose - a compromise that prevents the effective eradication of tumour cells.

For decades, radiotherapists have not been able to greatly improve the situation. They believe that even a 5-20% increase in the therapeutic window could drastically change clinical output. French nanomedicine specialist Nanobiotix has developed NanoXray, a formulation of inert, inorganic particles with a size of 50nm that can be delivered selectively to tumour cells. Consisting of hafnium oxide, they react to a standard radiation dose by emitting a shower of electrons. This is the identical physical mode of action of radiotherapy – except that hafnium oxide emits far more electrons than a water molecule, the usual target, and thereby locally increases the effective dose by a factor of nine. The radiotherapy dose in the surrounding healthy tissue is unaffected because it is not loaded with nanoparticles.

NanoXray can be administered without the need to invest in novel devices; it does not even require changes in standard radiation procedures. NanoXray is applied either via intra-tumoural injection (NBTXR3) or by deposition of a gel-formulation in the tumour bed during surgical resection (NBTX-TOPO). A formulation for intravenous injection (NBTXIV) is also in development.

EU regulated as a medical device, NBTXR3 is in a Phase I study in soft tissue sarcoma patients. Preliminary results are expected at the end of 2012.

05.11.2012

More on the subject:
Read all latest stories

Related articles

Photo

News • Flexible electronics and human stem cells

‘Biohybrid’ device could restore function in paralysed limbs

Cambridge researchers have developed a new type of neural implant that could restore limb function to amputees and others who have lost the use of their arms or legs.

Photo

News • Protein controls resistance

Targeted approach holds promise to improve chemotherapy

Chemotherapy resistance is a main cause of treatment failure and death in cancer patients. Researchers from Brussels found how cancer cells protect themselves from the aggressive treatment.

Photo

News • What's your sound barrier?

Misophonia: new insights into intolerance of everyday sounds

UK researchers have shown that misophonia, a condition where those affected show a strong negative reaction to everyday sounds, may affect almost one fifth of the general population.

Related products

Sarstedt – Low DNA Binding Micro Tubes

Research Use Only

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030 CL (IVD)/ CLAM-2030 (RUO)

Mass Spectrometry

Shimadzu – CLAM-2030 CL (IVD)/ CLAM-2030 (RUO)

Shimadzu Europa GmbH
Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Mass Spectrometry

Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Shimadzu Europa GmbH
Shimadzu – MALDImini-1

Research Use Only

Shimadzu – MALDImini-1

Shimadzu Europa GmbH
Subscribe to Newsletter